In its own review of RELIEVE-HF data, V-Wave highlighted the improvements seen in HFrEF patients.

“Between the United States and the European Union, there are 2 million to 3 million HFrEF patients with New York Heart Association Class III symptoms,” V-Wave CEO Neil Eigler, M.D., said in a statement. Ta. “The prognosis for these patients is worse than that of many cancers, leaving few options. This places a significant burden not only on the patients, but also on their families and the healthcare system. We are excited by the RELIEVE-HF results showing improvements in heart failure hospitalizations and other study endpoints, suggesting our investigational device has the potential to address these needs.”

EMPACT-MI: Empagliflozin after heart attack

Javed Butler, M.D., director of the Baylor Scott & White Institute, was next to take the stage to present the results of the EMPACT-MI randomized trial of treating patients with empagliflozin after a heart attack.

Butler’s team looked at data from more than 6,000 acute myocardial infarction (AMI) patients treated with empagliflozin, a popular SGLT-2 inhibitor sold under the brand name Jardiance, or a placebo. investigated.

Although treatment with empagliflozin did not significantly affect the study’s primary endpoint of combined heart failure hospitalization and all-cause mortality, it appeared to dramatically improve heart failure hospitalization rates when followed alone. For example, when treated with empagliflozin, patients were 23% less likely to be hospitalized for heart failure for the first time and 33% less likely to be hospitalized for heart failure. This risk reduction was consistent across all heart failure subgroups, Butler noted.

“When it comes to heart failure outcomes, the data are not only strong but consistent with what has been found in additional populations over the past decade,” he said. “This finding is fully consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”